MedTrace Logo

Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)

NCT03236688 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-10-06

No results posted yet for this study

Summary

Demonstrate detection of ARv7 splice variant transcripts from exosomes in the circulation of MCRPC patients pre and post treatment with selective Androgen pathway inhibitors (i.e. abiraterone and enzalutamide)

Conditions

  • Metastatic Castrate Resistant Prostate Cancer

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • Exosome Diagnostics, Inc.

    lead INDUSTRY

Principal Investigators

  • Roger Tun · Exosome Diagnostics, Inc.

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03236688 on ClinicalTrials.gov